Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CLNN
Clene Inc. (CLNN) EV/Sales
As of 16 October 2026, Clene Inc. (CLNN) trades at a EV/Sales of 239×. Over the past ten years it has ranged from 0.0× (December 2020) to 2,186× (April 2021); the current reading is higher than 68% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 331× | 181.72% |
| FY2024 | 118× | 926.68% |
| FY2023 | 11.4× | (90.65%) |
| FY2022 | 122× | (63.26%) |
| FY2022 | 333× | 8.90% |
| FY2021 | 306× | (16.37%) |
| FY2021 | 366× | (43.01%) |
| FY2020 | 642× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 431× | (14.81%) |
| Mar 2026 | 506× | 52.82% |
| Dec 2025 | 331× | 1.40% |
| Sep 2025 | 327× | 104.32% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −9.7× |
| ACET Adicet Bio, Inc. compare | −1.8× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| HOWL Werewolf Therapeutics, Inc. compare | 1.9× |
| IMA ImageneBio, Inc. compare | 2.5× |
| INMB INmune Bio, Inc. compare | 210× |
| CLNN Clene Inc. | 239× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)